转录因子EB与心肌缺血损伤的研究进展

Research progress of transcription factor EB and myocardial ischemic injury

摘要:

急性心肌梗死是由于心肌细胞持续缺血缺氧,进而导致心肌细胞坏死。再灌注治疗是减少梗死面积和改善心肌梗死预后的标准策略。然而,再灌注治疗带来的心肌损伤伴随着多种病理生理过程,如氧化应激、炎症反应、心肌纤维化、细胞外基质重构等。转录因子EB(TFEB)是自噬-溶酶体信号通路的中枢调控因子,参与应激反应、心肌能量代谢、自噬和溶酶体生物发生等信号通路,与心肌梗死后心肌损伤修复密切相关。本综述旨在阐述TFEB在心肌缺血损伤中的作用机制。

Abstract:

Acute myocardial infarction is caused by continuous ischemia and hypoxia of myocardial cells, leading to myocardial cell necrosis. Reperfusion therapy is the standard strategy for reducing infarct size and improving the prognosis of myocardial infarction. However, myocardial injury caused by reperfusion therapy is accompanied by various pathophysiological processes, such as oxidative stress, inflammatory response, myocardial fibrosis, extracellular matrix remodeling, etc. Transcription factor EB (TFEB) is a central regulatory factor in the autophagy-lysosome signaling pathway, involved in signaling pathways such as stress response, myocardial energy metabolism, autophagy, and lysosomal biogenesis. It is closely related to the repair of myocardial injury after myocardial infarction. This review aims to elucidate the mechanism of TFEB in myocardial ischemic injury.